For Investors

OUR LATEST INVESTOR INFORMATION

View our latest Investor Presentation to find the most recent investor-related information

Download PDF

Crystal Research Associates Executive Informational Overview, March 10, 2022

Download PDF

Latest News

FSD PHARMA INC. ANNOUNCES RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERS AND OTHER CORPORATE UPDATES

FSD PHARMA INC ANNOUNCES ANNUAL GENERAL MEETING OF SHAREHOLDERS

FSD PHARMA FILES INVESTIGATIONAL NEW DRUG APPLICATION (“IND”) WITH FDA AND HEALTH CANADA FOR PHASE-2 TRIAL OF FSD-201 FOR AN INFLAMMATORY DISORDER

FSD PHARMA ISSUES CIRCULAR, ADOPTS INCENTIVE PLAN AND GRANTS PSUS

FSD PHARMA CLOSES CAD$16.4 MILLION SALE OF NON-CORE ASSETS

Video released

More news

Competitive Advantage / VALUE PROPOSITION

World-Class Pipeline

Neurodegenerative and neuropsychiatric disease, multi-billion dollar markets, unmet need, decades of research de-risk our drugs

Lucid-MS: New Chemical Entity for Multiple Sclerosis, pre-clinical research re-established use of paralyzed rear legs in MS mouse model, research published in peer-reviewed journals, Phase 1 clinical trial targeted for Q4 2022

FSD-201: Proprietary ultra-micro PEA (palmitoylethanolamide) compound, solid safety profile in humans, Phase 2 clinical trials for inflammatory disease targeted Q2 2022

Lucid-Psych: Novel pathway (unique MOA) to treat Major Depressive Disorder, Phase 1 clinical trial targeted for Q4 2022

IP Estate: FSD Pharma has rights to patent families licensed on an exclusive basis

Elite Team

FSD Pharma’s flagship subsidiary led by Dr. Lakshmi Kotra, the recipient of the Julia Levy Award and a senior scientist at the Krembil Brain Institute, as well as the world-renowned University Health Network (UHN).

FSD Pharma has 6 PhD’s and 2 MD’s working full-time on pipeline development, with backgrounds at the FDA, major pharmaceuticals firms, and esteemed universities.

FSD Pharma team includes 2 Julia Levy Award recipients, a distinguished award that has only been awarded to 8 recipients since its inception in 2005 (no other company can make this claim)

Strong Cash Position

Cash significant for 3+ years of operations (including 3 planned clinical trials)

No dilution on horizon for shareholders

Solid Cap Table / Insider Ownership

Only 38.4 million shares issued

Cash position equates to CDN$1.30*

Share repurchase plan ongoing, 1.663 million shares returned to treasury as of 03 Jun 2022

Co-founders Zeeshan Saeed and Anthony Durkacz and other insiders frequently buying shares since start of 2022 and continue to accumulate

*Data current as of May 20, 2022

Industry classifications

Sector:

Healthcare

Industry:

Drug Manufacturers

NAICS:

Pharmaceutical
Preparation
Manufacturing (325412)

SIC:

Pharmaceutical and
Medicine Industry
(3741)

Stock data

ALL STOCK QUOTE

Market Data copyright © 2021 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
RT=Real-Time, EOD=End of Day, PD=Previous Day.
Market Data powered by QuoteMedia. Terms of Use.

Financial results

2022 2021 2020 2019 2018

Q1 2022

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL STATEMENTS for the three months ended March 31, 2022, and 2021

Earnings Release

PDF

SEC filling

Latest quarterly or annual filing

Annual reports filed by certain Canadian issuers pursuant to Section 15(d) and Rule 15d-4

DECEMBER 31, 2021

20-F

HTML PDF

Latest current report

Condensed consolidated interim financial statements for the three months ended March 31, 2022, and 2021

MAY 13, 2022

PDF

ALL SEC FILINGS

Annual Reports

SEDAR

Company Structure

Our leadership consists of a passionate management team with diverse industry knowledge, committed to science, therapeutic drug discovery and development.

BOARD OF DIRECTORS

...

EXPERT RESEARCH AND CLINICAL TEAM

...

MANAGEMENT TEAM

...

REGULATORY ADVISORY BOARD

...

Governance Documents

CODE OF CONDUCT AND ETHICS	PDF
NASDAQ CORPORATE GOVERNANCE DISCLOSURE STATEMENT	PDF

FAQ

What is FSD Pharma Inc.'s stock symbol?
Our stock is traded on the CSE under the symbol HUGE and on the Nasdaq under the symbol HUGE.
When was FSD Pharma Inc. incorporated?
November 1, 1998
When did FSD Pharma Inc. become a public company?
May 29, 2018
When is FSD Pharma Inc.'s fiscal year end?
December 31st

Who is FSD Pharma Inc.'s transfer agent?
Marrelli Support Services Inc. (MSSI)
Website
Who is FSD Pharma Inc.'s independent auditor?
MNP LLP
Website
Who is FSD Pharma Inc.'s outside legal counsel?
Blake, Cassels & Graydon LLP
Website